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Abstract
Background: The encephalopathy associated with autoimmune thyroid disease (EAATD) is characterized by 
neurological/psychiatric symptoms, high levels of anti-thyroid antibodies, increased cerebrospinal fluid protein 
concentration, non-specific electroencephalogram abnormalities, and responsiveness to the corticosteroid treatment 
in patients with an autoimmune thyroid disease. Almost all EAATD patients are affected by Hashimoto's thyroiditis (HT), 
although fourteen EAATD patients with Graves' disease (GD) have been also reported.
Methods: We have recorded and analyzed the clinical, biological, radiological, and electrophysiological findings and 
the data on the therapeutic management of all GD patients with EAATD reported so far as well as the clinical outcomes 
in those followed-up in the long term.
Results: Twelve of the fourteen patients with EAATD and GD were women. The majority of GD patients with EAATD 
presented with mild hyperthyroidism at EAATD onset or shortly before it. Active anti-thyroid autoimmunity was 
detected in all cases. Most of the patients dramatically responded to corticosteroids. The long term clinical outcome 
was benign but EAATD can relapse, especially at the time of corticosteroid dose tapering or withdrawal. GD and HT 
patients with EAATD present with a similar clinical, biological, radiological, and electrophysiological picture and require 
an unaffected EAATD management.
Conclusions: GD and HT equally represent the possible background condition for the development of EAATD, which 
should be considered in the differential diagnosis of all patients with encephalopathy of unknown origin and an 
autoimmune thyroid disease, regardless of the nature of the underlying autoimmune thyroid disease.
Background
Encephalopathy associated to autoimmune thyroid dis-
ease (EAATD), also called Hashimoto's encephalopathy,
is a rare condition that may occur in patients with clinical
or sub-clinical autoimmune thyroid disease. It is charac-
terized by unspecific and protean neurological and/or
psychiatric symptoms often associated with high serum
and/or cerebrospinal fluid (CSF) levels of anti-thyroid
antibodies (Abs), increased CSF protein concentration,
non-specific diffuse electroencephalogram (EEG) abnor-
malities, and responsiveness to the treatment with corti-
costeroids [1-4]. The diagnosis of EAATD is still based
mostly on exclusion criteria, which might affect the accu-
rate estimation of its genuine prevalence.
Several mechanisms, like cerebral autoimmune vasculi-
tis with focal or global brain hypoperfusion, cerebral tis-
sue-specific autoimmunity with or without
demyelination, and neuronal dysfunction secondary to
brain edema have been thought to be involved in the
pathogenesis [1,2,5-12]. Generally, EAATD occurs in
patients with normal, or slightly abnormal, thyroid hor-
m o n e  l e v e l s  a n d  s e e m s  t o  b e  u n r e l a t e d  t o  t h e  t h y r o i d
function [2,4,8]. Anti-thyroperoxidase (TPO) and anti-
thyroglobulin (TG) Abs have been often detected in the
CSF of EAATD patients but their possible role in the
pathogenesis has been not defined [2]. Novel antigens,
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like α-enolase and a 36-kDa protein present in a soluble
fraction from the cerebral cortex, have been recently
identified in EAATD patients but their involvement in
the pathogenesis has been not documented enough
[9,10]. Converging evidences support the hypothesis of
E A A T D  a s  a  c e r e b r a l  a u t o i m m u n e  v a s c u l i t i s  w i t h  o r
without immune-complex deposition [3,6].
The clinical manifestations range from stroke-like focal
signs to generalized symptoms, either with dramatic or
blunted presentation. Seizures, loss of consciousness,
cognitive alterations, hallucinations and psychiatric dis-
orders, behavioral changes, myoclonus, involuntary
movements including tremors, ataxia, language impair-
ment, sensory deficits, headache, and inflammatory signs
of encephalitis and/or meningitis have been frequently
reported [2,4,11,12].
The onset of EAATD may be acute or sub-acute and the
following trend progressive or relapsing. By definition,
EAATD symptoms are steroid-responsive, but spontane-
ous remission or lack of responsiveness to corticosteroids
rarely occurs. The prognosis appears depending on the
responsiveness to the corticosteroid treatment but the
evolution of the disease in the long-term is unpredictable.
Almost all patients with EAATD present with Hashim-
oto's thyroiditis (HT) as the background autoimmune
thyroid disease. Only a small number of EAATD patients
with a diagnosis of Graves' disease (GD) have been
reported to date [3,13-24]. We hereby review the full case
series of EAATD patients with GD published so far and
report the clinical manifestations, the evolution in the
long-term, and the outcomes in these patients.
Methods
The cases of EAATD in patients with GD published in the
international medical literature up to 2009, August 31st
h a v e  b e e n  s e a r c h e d  b y  t h e  I n t e r n e t  s c i e n t i f i c  r e s e a r c h
engine PubMed. "Hashimoto's encephalopathy", "enceph-
alopathy associated to/with autoimmune thyroid dis-
ease", "encephalopathy", "Graves' disease", and
"hyperthyroidism" have been used as both isolated and
crossed keywords. No limits have been imposed to the
research. A total number of 83788 published papers (all
article types) were found. Following review of the
abstracts or the full texts, the majority of the papers were
excluded (papers appearing repetitively at the PubMed
searches, falling out of topic, reporting cases of EAATD
in HT, reporting cases of GD without EAATD, or report-
ing research in animals or in vitro solely). Finally, 13
papers that describe and characterize cases of EAATD
occurred in patients with a defined diagnosis of GD were
identified, accounting for a total of fourteen patients
[3,13-24]. In the cases detected, the diagnosis of GD and
EAATD were done according to the current criteria. Fea-
tures compatible with EAATD without a defined diagno-
sis of the disease were disclosed in three GD patients
[25,26]. Language limitations (Japanese, Slovak) and
availability of the abstract only did not allow the proper
data collection for confirming GD diagnosis and report-
ing exhaustively the clinical and biological features of two
patients [27,28]. These five patients have been not listed
in our case series.
The data on the main anthropometric features, thyroid
function, serum and CSF levels of anti-TPO, anti-TG, and
anti-TSH Abs, imaging and EEG findings, and EAATD
sym p t o ms  ha ve  bee n c o llect ed a nd an al yzed.  T h e pe r -
sonal collaboration and the confidential data exchange
among the authors allowed the data collection and analy-
sis.
In the patient series, the concomitant presence of other
pathological conditions potentially linked to thyroid or
systemic autoimmunity has been checked. When possi-
ble, the patients were re-evaluated in the follow-up. In
such cases, the length of the follow-up and the clinical
and therapeutic outcomes were recorded, including data
about EAATD reoccurrences. The numerical data was
calculated as mean ± standard deviation and range
(patient age, duration of the follow-up, duration of the
corticosteroid treatment) or rates (EAATD symptoms,
biological findings). A comparison of the most relevant
immunological, CSF, magnetic resonance imaging (MRI),
and EEG findings reported in GD patient series versus a
homogeneous series of HT patients [12] with EAATD
was performed and two-tailed Fisher exact test has been
used for the statistical analysis.
Results
Anthropometric and clinical features
Fourteen patients with a defined diagnosis of GD and
EAATD have been recorded (Table 1), of which twelve
were females. Patient mean age at EAATD onset was 43.8
± 19.7 years (range: 12-79 years). Altered consciousness
(12/14), involuntary movements (including tremor and
myoclonus) (8/14), seizures (7/14), and cognitive impair-
m e n t  ( 6 / 1 4 )  w e r e  t h e  m o s t  f r e q u e n t l y  r e p o r t e d  s y m p -
toms. Sensorial alterations, headache, focal symptoms,
ataxia, language impairment, signs of encephalitis, and
psychiatric symptoms have been also described. All
patients but one, which spontaneously improved, were
treated with corticosteroids and they showed a dramatic
improvement of EAATD symptoms with the exception of
two cases (Patient 7 responded partially, Patient 8 did not
respond and required administration of intravenous
immunoglobulins). Patient 4 had plasmapheresis associ-
ated to the administration of corticosteroids. Methyl-
prednisolone 1000 mg daily (or equivalent) as attack dose
for a few days followed by oral corticosteroids with a slow
and progressive tapering of the daily dose was the most
used treatment outline.Tamagno et al. BMC Neurology 2010, 10:27
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Table 1: Patients with Graves' disease and encephalopathy associated with autoimmune thyroid disease.
Reference Age Gender Clinical manifestations EAATD relapses
(in the short term)
Thyroid 
hormones
Responsiveness to 
corticosteroid therapy
Patient 1 [3] 21  seizures, involuntary 
movements, altered 
consciousness
no - hyperthyroidism - clinical improvement
- decrease of the auto-Abs
Patient 2 [13] 23  seizures, cognitive impairment, 
altered consciousness
1 relapse - hyperthyroidism
- euthyroidism at 
EAATD relapse
- clinical improvement
- decrease of the auto-Abs
Patient 3 [14] 51  involuntary movements, 
cognitive impairment, 
decreased verbal fluency, 
altered consciousness
1 relapse - hyperthyroidism
- euthyroidism at 
EAATD relapse
- clinical improvement
- decrease of the auto-Abs
Patient 4 [15] 45  involuntary movements, 
mono-lateral weakness, 
dysarthria, altered 
consciousness, hallucinations, 
sphincters incontinence
no - hyperthyroidism - clinical improvement
- decrease of the auto-Abs
- plasmapheresis was 
required
Patient 5 [16] 29  headache, altered hearing, 
nausea and vomit, blunted 
papilla, nystagmus
no - hyperthyroidism - clinical improvement
- decrease of the auto-Abs
Patient 6 [17] 57  involuntary movements, 
altered consciousness
no not reported - clinical improvement
Patient 7 [17] 25  seizures, headache, 
involuntary movements, 
ataxia, aphasia, altered 
consciousness
persisting 
symptoms
not reported - partial improvement
Patient 8 [18] 12  optic neuritis, dysmetria, 
dysdiadochokinesis
no - hyperthyroidism - clinical worsening
Patient 9 [19] 68  seizures, altered 
consciousness, anxiety, 
hallucinations
no - euthyroidism - clinical improvement
Patient 10 [20] 61  involuntary movements, 
ataxia, cognitive impairment, 
altered consciousness, 
depression
no - post-RAI 
hypothyroidism
- clinical improvement
Patient 11 [21] 47  seizures, headache, 
hemiplegia, cognitive 
impairment, altered 
consciousness, hallucinations
no - hyperthyroidism - clinical improvement
- decrease of the auto-AbsTamagno et al. BMC Neurology 2010, 10:27
http://www.biomedcentral.com/1471-2377/10/27
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Only 4/14 cases of Graves' ophthalmopathy have been
reported (Patient 3, 4, 10, and 12). No other GD-related
clinical manifestations, including myopathy and dermop-
athy, were described. None of the patients presented with
other autoimmune diseases, like gastritis and arthritis
prior to EAATD occurrence. After the diagnosis of
EAATD, Patient 10 developed acquired autoimmune
hemophilia with anti-factor VIII Abs despite the concom-
itant corticosteroid treatment and thereafter was treated
also with cyclophosphamide.
Biological findings
Evidence of mild/moderate or subclinical hyperthyroid-
ism at EAATD onset, or a few weeks before it, was
reported in all patients except Patient 12, euthyroid, and
Patient 10, with post-radioactive iodine hypothyroidism
not adequately replaced. All patients had evidence of
active anti-thyroid autoimmunity in their serum samples
but the complete panel of anti-thyroid Abs (anti-TG, anti-
TPO, and anti-TSH receptor Abs) was assessed in seven
patients only (Patient 1, 3, 5, 10, 11, 12, and 13). Serum
anti-TPO Abs were positive in all cases (14/14). Serum
anti-TG and anti-TSH receptor Abs were positive in 7/11
(Patient 1, 3, 4, 5, 6, 7, and 13) and 9/10 (Patient 1, 2, 3, 5,
8, 11, 12, 13, and 14) patients, respectively. In the CSF,
anti-TPO and anti-TG Abs were positive in 5/5 (Patient 2,
6, 7, 10, and 14) and 2/2 (Patient 6 and 7) cases, respec-
tively. Anti-TSH receptor Abs were assayed in the CSF of
Patient 5 only with negative result. The CSF protein con-
centration was increased in 7/11 patients (Patient, 1, 2, 3,
4, 10, 11, and 14). In Patient 9, the CSF protein level
ranged inside the reference limits but the IgG and albu-
min CSF/serum ratios were slightly elevated. In five
patients, mild lymphocytic pleocytosis was disclosed
(Patient 4, 5, 8, 9, and 10).
Imaging and EEG findings
B r a i n  c o m p u t e d  t o m o g r a p h y  ( C T )  w a s  n o r m a l  i n  3 / 4
(Patient 5, 12, and 13) but showed an inflammatory pat-
tern in Patient 9. MRI showed normal or not relevant
findings in 9/13 patients (Patient 1, 2, 3, 4, 6, 9, 11, 13, and
14). Patient 5 presented with non-specific signal changes
of the white matter, cerebral edema, and parenchyma
alterations compatible with inflammation. Isolated
hyperintense white matter changes were seen in 3/12
patients and were reversible (Patient 8, 10, and 12). In
Patient 4, the brain MRI was normal but a severe stenosis
of the internal carotid arteries and arteries distal to the
basilar artery was revealed by magnetic resonance
angiography and improved after EAATD treatment.
However, the angiogram was normal in Patient 12 who
had abnormal MRI findings. A global reduction of brain
perfusion was demonstrated by single photon emission
computed tomography (SPECT) in Patient 2 and Patient
13, both having unremarkable MRI findings. In Patient 3,
positron emission tomography revealed a diffuse hypo-
metabolic cerebral pattern that recovered after the
EAATD symptoms disappeared. The EEG records were
abnormal in 12/13 patients (Patient 1, 2, 3, 4, 5, 7, 9, 10,
11, 12, 13, and 14). A diffuse and not specific slowing of
the background EEG activity was the most frequent
record (Patient 1, 2, 3, 4, 5, 10, 11, 12, and 14).
Follow-up
Patient 2, Patient 3, and Patient 14 showed a relapse of
EAATD in the short-term clinical course. These events
occurred with a concomitant euthyroid state under anti-
thyroid therapy in the first two patients and iatrogenic
very mild hypothyroidsm in Patient 14. In Patient 2,
EAATD relapsed one month after the first episode. In the
other two cases, the recurrence of EAATD symptoms was
Patient 12 [22] 40  seizures, hemiplegia, dysathria, 
cognitive impairment, altered 
consciousness
no - hyperthyroidism - no corticosteroid 
treatment
- spontaneous 
improvement
Patient 13 [23] 79  seizures, involuntary 
movements, cognitive 
impairment, altered 
consciousness
not reported - hyperthyroidism - clinical improvement
Patient 14 [24] 55  involuntary movements, 
ataxia, altered consciousness, 
anxiety, hallucinations
1 relapse - hyperthyroidism
- very mild 
hypothyroidism 
at EAATD relapse
- clinical improvement
- decrease of the auto-Abs
The main anthropometrics data, biological findings, and clinical features of the fourteen patients with a defined diagnosis of Graves' disease and 
encephalopathy associated with autoimmune thyroid disease (EAATD) reported in the literature so far (Abs: antibodies; RAI: radioactive iodine).
Table 1: Patients with Graves' disease and encephalopathy associated with autoimmune thyroid disease. (Continued)Tamagno et al. BMC Neurology 2010, 10:27
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concomitant with the early corticosteroid dose tapering
(Patient 3) or withdrawal (Patient 14) and was promptly
reversed by restoring an effective daily corticosteroid
dose in the first case and thyroidectomy in the second
one. Both patients experienced the relapse about two
weeks after the first EAATD occurrence.
Original data regarding the long-term follow-up and
outcomes have been recorded in six patients (Patient 1, 4,
5, 10, 12, and 14) (Table 2). Two patients (Patient 3 and
Patient 9) were lost at the long-term follow-up. There is
no data about the lasting six patients available (Patient 2,
6, 7, 8, 11, and 13). The average follow-up duration of the
six patients fully described in the long-term was 37.5 ±
11.0 months (range: 26-54 months). After the recovery
from the EAATD episode, only patient 10 had a relapse
(month 21). This event was concomitant to the corticos-
teroid dose tapering. The corticosteroid therapy was ben-
eficial in 4/4 patients receiving such a treatment in the
long-term and was withdrawn in three of them in 14.0 ±
8.5 months (range: 6-23 months). Patient 10 did not stop
his corticosteroid treatment. On the contrary, Patient 12
did not receive corticosteroids because of spontaneous
improvement of EAATD and experienced no relapses up
to her last follow-up visit (month 26). Patient 14 did not
receive any corticosteroid treatment after total thyroidec-
tomy and remained asymptomatic during the follow-up
so far (month 30). GD relapsed in 2/6 patients (Patient 1
and Patient 5) and radioiodine and total thyroidectomy
were needed, respectively. During the follow-up, neither
classical extra-thyroid GD manifestations nor other auto-
i m m u n e  d i s e a s e s  w e r e  r e p o r t e d  i n  a n y  p a t i e n t s  b u t
Patient 10 who developed autoimmune hemophilia
(month 24). Actually, Patient 10 was the only case of
EAATD relapse in the long-term follow-up, occurring
t hr ee mont hs before t he r eport of a utoimm une hemo-
philia. The combination of the above conditions required
a combined treatment with corticosteroids and cyclo-
phosphamide, both still ongoing at his last follow-up visit
(month 33).
Discussion
Altered consciousness, involuntary movements (includ-
ing tremor and myoclonus), seizures, cognitive impair-
ment, focal neurological signs, ataxia, sensorial
alterations, language impairment, symptoms of encepha-
litis (i.e., headache and nausea), and psychiatric altera-
tions are the clinical manifestations of EAATD reported
in GD patients. The hugely variable EAATD presentation
in GD mirrors that occurring in HT patients. In both
conditions, EAATD clinical manifestations can be fluctu-
ating and relapsing. A rigorous statistical comparison of
EAATD manifestations between the two groups is not
realistic at the present stage due to the remarkable
numerical difference of the two groups, the discrepancies
in reporting the clinical data, and the virtually unlimited
spectrum of the neurological and psychiatric symptoms
and signs by which EAATD can manifest. All GD patients
with EAATD and available hormonal data (12/14) had
increased thyroid hormones at EAATD onset or few
weeks before it, except one case of post-radioactive
iodine hypothyroidism and one case of euthyroidism. The
three patients which experienced a relapse of EAATD in
the short-term presented with biochemical euthyroidism
(two patients) or very mild iatrogenic hypothyroidism
(one patient) when the encephalopathy reoccurred. Six
cases of possible but not clearly defined GD, HT thyro-
toxicosis, and non-GD-related hyperthyroidism concom-
itant to the occurrence of EAATD symptoms has been
described as well [29-32]. On the other hand, a large
number of HT patients presents with clinical or sub-clin-
ical hypothyroidism at EAATD onset. Altogether, these
data suggest that the hormonal changes are irrelevant in
regard to the occurrence of EAATD that can develop
independently from high, normal, or low thyroid hor-
mone levels.
Anti-thyroid autoimmunity was active in all patients of
the series described above, as documented by the anti-
TPO Abs positivity. Anti-α-enolase and anti-neuronal
Abs [9,10,33] are now getting relevance as possible diag-
nostic markers of EAATD but their use in the clinical
practice is still limited. These auto-Abs have never been
assayed in GD patients. Anti-TSH receptor Abs have
been assayed by a radio-receptor method in the CSF of
one GD patient only and were found negative. A link
between enhanced anti-thyroid autoimmunity and the
occurrence of EAATD seems to be a realistic hypothesis
as suggested by the positive anti-TPO Abs. Indirectly, the
hyperthyroidism caused by the anti-TSH receptor Abs at
the time of the EAATD appearance in many GD patients
confirms the same. However, the nature of the auto-Abs
involved in the pathogenesis of EAATD and the mecha-
nisms that cross anti-thyroid autoimmunity and enceph-
alopathy are still undefined. The analysis of the CSF
shows that an unspecific and mild inflammatory state can
be detected in GD as well as HT patients with EAATD.
The morphological analysis of the brain by the conven-
tional radiological methods does not provide any specific
findings but strongly contributes to the diagnosis because
of the exclusion of other possible causes of the neurologi-
cal or psychiatric symptoms. Interestingly, the hyperin-
tense white matter changes occasionally detected at MRI
appear to be reversible as previously reported also in case
of HT [34]. In selected cases, imaging methods that study
t h e  vas cu l a r  fu n ct i o n  o f  t h e  b r a i n ,  l i k e  m a gn e t i c  r e s o -
nance angiography and SPECT, can be useful tools for the
diagnosis of EAATD. The findings from patients that
underwent these procedures are compatible with the
hypothesis of vasculitis or a vascular defect secondary toTamagno et al. BMC Neurology 2010, 10:27
http://www.biomedcentral.com/1471-2377/10/27
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Table 2: Long-term follow-up of eight patients with Graves' disease and encephalopathy associated with autoimmune 
thyroid disease.
Reference Follow-up
(months)
Anti-thyroid Abs
(serum)
GD relapses EAATD relapses Other 
autoimmune 
manifestations
Treatment
Patient 1 [3] 34 - normal anti-TG, 
anti-TPO, and anti-
TSH Receptor Abs
1 relapse
(month 18)
no no - prednisone
(from month 1 to month 23)
- RAI
(month 20)
- levothyroxine
(from month 24)
Patient 3 [14] lost at follow-up
Patient 4 [15] 48 - normal anti-TG Abs
- increased anti-TPO 
Abs
no no no - prednisone
(from month 1 to month 13)
- propylthiouracil
(from month 1 to month 4 
and from month 18 to 40)
- radioiodine therapy
(month 6)
- total thyroidectomy
(month 32)
Patient 5 [16] 54 - normal anti-TG, 
anti-TPO, and anti-
TSH Receptor Abs
1 relapse
(month 20)
no no - prednisone
(from month 1 to month 6)
- propylthiouracil
(from month 1 to month 18 
and from month 20 to 45)
- total thyroidectomy
(month 45)
- levothyroxine
(from month 45)
Patient 9 [19] lost at follow-up
Patient 10 [20] 33 - normal anti-TG and 
anti-TSH Receptor 
Abs
- increased anti-TPO 
Abs
no 1 relapse (month 
21)
autoimmune 
hemophilia (anti-
factor VIII Abs +)
- levothyroxine
(starting before EAATD 
occurrence)
- prednisolone
(from month 1)
- cyclophosphamide
(from month 24)
Patient 12 [22] 26 - normal anti-TG Abs
- increased anti-TPO 
and anti-TSH 
Receptor Abs
no no no - methimazole
(from month 1)
Patient 14 [24] 30 - normal anti-TG Abs
- increased anti-TPO 
and anti-TSH 
Receptor Abs
no no no - methylprednisolone
(month 1)
- total thyroidectomy
(month 1)
- levothyroxine
(from month 1)
Anti-thyroid antibodies (Abs), clinical outcomes, and management in the long-term follow-up of eight out of fourteen patients with Graves' 
disease (GD) and encephalopathy associated with autoimmune thyroid disease (EAATD). The serum anti-thyroid Abs were assessed at the last 
follow-up vist, which took place at the reported follow-up month for each single patient (TG: thyroglobulin; TPO: thyroperoxidase; TSH: thyroid 
stimulating hormone; RAI: radioactive iodine).Tamagno et al. BMC Neurology 2010, 10:27
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brain inflammation in the EAATD pathogenesis. The
EEG patterns recorded in EAATD patients are unspecific,
but a diffuse slowness of the background rhythm is the
most common and characteristic report. Interestingly, a
comparison of the laboratory, imaging, and electrophysi-
ological findings of GD and HT patients with EAATD
show no significant differences between the two groups
(Table 3).
Four cases of Graves' ophthalmopathy among the four-
teen patients with GD and EAATD have been reported.
One of them had an EAATD relapse during the long-term
follow-up and developed also autoimmune hemophilia.
He required an aggressive immunosuppressive treatment.
This case is an exception in the series of GD patients with
EAATD in regard to the gender (one of the two males),
extra-thyroid GD manifestations, and therapeutic issues.
After the analysis of the patient series hereby reported,
we are induced to postulate that the central nervous sys-
tem should be enlisted among the possible extra-thyroid
targets of GD and, thus, encephalopathy should be con-
sidered as a rare extra-thyroid manifestation of GD.
The majority of the patients had an impressive clinical
and immunological improvement after the corticosteroid
treatment, including the cases in which EAATD relapsed.
This event was usually concomitant with the tapering or
precocious withdrawal of the corticosteroids. We think
that a one-year-long corticosteroid treatment represents
a reasonable and advisable baseline therapeutic plan.
Administration of a daily high-dose of corticosteroids
during the acute phase of EAATD followed by a slow and
careful dose tapering to withdrawal appears to be an
effective therapeutic approach. In one case of the above
series of GD patients, thyroidectomy after EAATD
relapse led to a progressive and rapid improvement of the
symptoms without any concomitant corticosteroid
administration. This interesting report could suggest that
thyroid antigens may play a direct role in the pathogene-
sis of EAATD by triggering the immunological reaction
leading to encephalopathy.
Conclusions
In conclusion, we show that GD can represent the back-
ground condition underlying EAATD. The clinical,
immunological, radiological, electrophysiological, and
therapeutic features of EAATD in GD do not differ from
those of HT patients. The lack of differences in EAATD
manifestations, findings, and outcomes between patients
with GD and HT suggests that the diagnosis of EAATD
should be considered in all patients with signs of enceph-
alopathy of unknown origin and an autoimmune thyroid
disease, independently by the functional status of the thy-
roid and the nature of the underlying autoimmune thy-
roid disease itself.
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